NetraMark Holdings Inc. is a Canada-based technology company specializing in artificial intelligence (AI) and machine learning (ML) solutions for the pharmaceutical industry. Its primary focus is de-risking clinical trials by analyzing complex patient data to identify precise patient personas based on placebo response, drug efficacy, tolerability, and adverse events. The company's proprietary topology-based algorithms parse heterogeneous datasets into related subsets, enabling effective use of small data volumes alongside traditional AI/ML methods. Key products include NetraAI for trial optimization, Netra Shatter, Netra Health Atlas, NetraPlacebo for placebo response analysis, and Netra GPT for literature-based insights. Operating in the healthcare software and health information services sectors, NetraMark Holdings Inc. supports trial sponsors, clinical research organizations, and biotech firms. Founded in 2016 as Nurosene Health Inc. and rebranded in 2023, it is headquartered in Toronto and led by CEO George Achilleos and Chief Scientific Officer Joseph Geraci.